 |
|
|
| |
Absence of a Significant Pharmacokinetic Interaction Between the HCV Protease Inhibitor Boceprevir and HIV-1 NNRTI Rilpivirine
|
| |
| |
Reported by Jules Levin
CROI 2013
Elizabeth G. Rhee, Hwa-ping Feng, Fengjuan Xuan, Wen H. Lin, Candice B. Smith, Yali Zhu, Joan R. Butterton
Merck, Whitehouse Station, NJ, USA
|
| |
|
|
|
|
|
